Inactive Instrument

Inter Pharma Stock OTC Markets

IPTB.F

TH9474010005

Interpharma Public Company Limited is a Thailand-based company that develops, researches and distributes healthcare products and beauty initiatives for human beings, and healthcare products for animals. The Company provides wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. Its products include PREBO, YUUU toothpaste, multivitamin, Probac 7, Probac 10, Beta Glucan Plus, Pure Krill Oil, Astacurmin, YUUU cleansing mousse, Perfectha Complement, Perfectha Derm, Perfectha Deep, Perfectha Subskin and Uderma.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Market Cap	3B 89.38M 78.7M 74.57M 67.32M 127M 8.57B 129M 892M 343M 4.38B 336M 328M 14.05B	P/E 2024	52.3x	P/E 2025	22.8x
Enterprise Value	3.12B 92.93M 81.83M 77.53M 70M 132M 8.91B 134M 928M 357M 4.56B 349M 341M 14.6B	EV / Sales 2024	1.13x	EV / Sales 2025	1.31x
Free-Float	-	Yield 2024 *	-	Yield 2025	1.59%

Aug. 14	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
May. 11	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 02	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 01	Inter Pharma Public Company Limited announces Annual dividend, payable on May 25, 2026	CI
Nov. 11	Inter Pharma Public Company Limited (SET:IP) agreed to acquire an additional 49% stake in Interpharma- ZEAvita Company Limited from Thai Union Ingredients.	CI
Nov. 11	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-13	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal	MT
25-04-16	Zhaoke Ophthalmology Limited Enters into Three Distribution and Supply Agreements with Interpharma Public Company Limited	CI
25-04-01	Inter Pharma Public Company Limited Signs Exclusive Distribution Agreement with Zhaoke Ophthalmology Company Limited for Comprehensive Eye Care Innovation	CI
25-02-25	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-25	Inter Pharma Public Company Limited Proposes to Omit Dividend Payment for the Year Ended December 31, 2024	CI

22-08-16	Inter Pharma : New shares of IP to be traded on August 18, 2022	PU
22-08-10	Inter Pharma Public : Notification on Change of Directors and Authorization of Directors	PU
22-08-10	Inter Pharma Public : Report on the results of sale of common shares offered to private placement (F53-5)	PU
22-08-10	Inter Pharma Public : Right Adjustment of IP-W1 (Edited)	PU
22-08-09	Inter Pharma Public : Right Adjustment of IP-W1	PU

Manager	Title	Age	Since
Trinnawat Thanitnithiphan CEO	Chief Executive Officer	56	2014-01-31
Chatkaew Krudkosol DFI	Director of Finance/CFO	56	2023-06-22
Chompunuch Meevang CMP	Compliance Officer	54	-

Director	Title	Age	Since
Napaporn Dechakarat BRD	Director/Board Member	51	2017-06-13
Sansanee Chaiyaroj BRD	Director/Board Member	64	2020-07-31
Trinnawat Thanitnithiphan BRD	Director/Board Member	56	2014-01-31

Inter Pharma Stock OTC Markets

Stocks

IPTB.F

TH9474010005

Pharmaceuticals

Valuation: Inter Pharma

Latest news: Inter Pharma

Press Releases: Inter Pharma

Managers and Directors: Inter Pharma

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTER PHARMA	-.--%	-.--%	-	-	89.38M
ELI LILLY AND COMPANY	-2.33%	+0.53%	+51.65%	+115.42%	1,031B
JOHNSON & JOHNSON	-1.06%	-1.65%	+42.78%	+69.98%	638B
ABBVIE INC.	-0.65%	-1.32%	+12.98%	+75.49%	462B
MERCK & CO., INC.	-2.66%	-1.87%	+73.13%	+41.15%	359B
ROCHE HOLDING AG	-0.64%	-4.49%	+22.95%	+39.93%	335B
NOVARTIS AG	-1.54%	-0.55%	+13.73%	+26.70%	273B
ASTRAZENECA PLC	-2.00%	-2.55%	-2.83%	+10.36%	253B
AMGEN INC.	-0.50%	+3.80%	+49.37%	+56.84%	228B
GILEAD SCIENCES, INC.	-1.47%	-1.53%	+34.28%	+98.89%	185B
Average	-0.96%	-0.36%	+33.11%	+59.42%	418.21B
Weighted average by Cap.	-1.17%	-0.35%	+37.48%	+71.16%

	2024	2025
Net sales	1.91B 56.91M 50.12M 47.49M 42.87M 80.8M 5.46B 81.84M 568M 219M 2.79B 214M 209M 8.94B	2.21B 65.91M 58.04M 54.99M 49.64M 93.56M 6.32B 94.77M 658M 253M 3.23B 247M 242M 10.36B
Net income	37.28M 1.11M 977K 926K 836K 1.58M 106M 1.6M 11.08M 4.26M 54.39M 4.17M 4.08M 174M	122M 3.64M 3.21M 3.04M 2.74M 5.17M 349M 5.24M 36.36M 13.99M 179M 13.68M 13.38M 572M
Net Debt	209M 6.22M 5.48M 5.19M 4.68M 8.83M 596M 8.94M 62.08M 23.89M 305M 23.35M 22.84M 977M	119M 3.55M 3.13M 2.96M 2.67M 5.04M 340M 5.11M 35.45M 13.64M 174M 13.33M 13.04M 558M